As if informed investors need any additional words
of warning on high-risk companies caught up in the coronavirus frenzy,
Citron Research tweeted this morning about the dubious claims made by Inovio Pharmaceuticals (INO +10.6%),
up eight-fold since early October 2019, that it designed a COVID-19
vaccine in three hours after receiving the genetic sequence of the
SARS-CoV-2 virus. Citron regards its claim as “ludicrous” and
“dangerous,” adding that the SEC should suspend trading in the company’s
shares.
Unsurprisingly, Citron believes the stock will promptly return to the $2-range after the market’s animal spirits subside.
Informed investors also know that Inovio is not alone here.
https://seekingalpha.com/news/3549774-citron-warns-on-covidminus-19-play-inovio-pharmaceuticals
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.